UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

ResMed's share price dip reflects investor caution around how Eli Lilly ... But if Zepbound proves effective in apnea relief, it could temper demand growth for traditional CPAP machines by offering an ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

KeyBanc raised the firm’s price target on ResMed (RMD) to $280 from $266 on higher estimates and multiple, while keeping an Overweight rating ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

Citi analyst Mathieu Chevrier raised the firm’s price target on ResMed (RMD) to A$41 from A$38 and keeps a Neutral rating on the shares ...

RMD stock opened at $236.66 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.92 and a quick ratio of 1.91. ResMed has a 52-week low of $170.56 and a 52-week high of ...

We think ResMed’s intangible brand has also enabled significant price premiums over less well ... device category and 30% higher in the CPAP category. This may reflect higher reimbursement ...

Learn More The ResMed Inc (ASX: RMD) share price is under pressure on Monday. In morning trade, the sleep disorder treatment company's shares are down over 4% to $38.35. Investors have been ...

CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...